The Clinical Trials Transformation Initiative reflects on 10 years of working to improve the quality and efficiency of clinical trials. This article highlights many of the Clinical Trials Transformation Initiative’s accomplishments and offers examples of the impact that the Clinical Trials Transformation Initiative has had on the clinical trials enterprise. After conducting more than 25 projects and issuing recommendations for specific strategies to improve the design and execution of clinical trials, some common themes and lessons learned have emerged. Lessons include the importance of engaging many stakeholders, advanced planning to address critical issues, discontinuation of non-value added practices, and new opportunities presented by technology. Through its work, the Clinical Trials Transformation Initiative has also derived some operational best practices for conducting collaborative, multi-stakeholder projects covering project selection, project team dynamics and execution, and multi-stakeholder meetings and team discussions. Through these initiatives, the Clinical Trials Transformation Initiative has helped move the needle toward needed change in the clinical trials enterprise that has directly impacted stakeholders and patients alike.
Get full access to this article
View all access options for this article.
References
1.
TenaertsPMadreLArchdeaconPet al. The Clinical Trials Transformation Initiative: innovation through collaboration. Nat Rev Drug Discov2014; 13: 797–798.
Meeker-O Connell’AGlessnerCBehmMet al. Enhancing clinical evidence by proactively building quality into clinical trials. Clin Trials2016; 13: 439–444.
7.
BloomDBeetschJHarkerMet al. The rules of engagement: CTTI recommendations for successful collaborations between sponsors and patient groups around clinical trials. Ther Innov Regul Sci. Epub ahead of print 27July2017. DOI: 10.1177/2168479017720247.
8.
LandrayMJGrandinettiCKramerJMet al. Clinical trials: rethinking how we ensure quality. Ther Innov Regul Sci2012; 46: 657–660.
ArangoJChuckTEllenbergSSet al. Good clinical practice training: identifying key elements and strategies for increasing training efficiency. Ther Innov Regul Sci2016; 50: 480–486.
The Office of the Secretary and the Food and Drug Administration. Human subjects research protections: enhancing protections for research subjects and reducing burden, delay, and ambiguity for investigators. Fed Regist2011; 76(143): 44512
24.
EapenZJLauerMSTempleRJ. The imperative of overcoming barriers to the conduct of large, simple trials. JAMA2014; 311: 1397–1398.
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH), Office of Good Clinical Practice (OGCP), Office of Regulatory Affairs (ORA). Guidance for industry: oversight of clinical investigations—a risk-based approach to monitoring, https://www.fda.gov/downloads/Drugs/Guidances/UCM269919.pdf (2013, accessed 19 December 2017).
LentzJKennettMPerlmutterJet al. Paving the way to a more effective informed consent process: recommendations from the Clinical Trials Transformation Initiative. Contemp Clin Trials2016; 49: 65–69.
National Academies of Sciences, Engineering, and Medicine. Enabling precision medicine: the role of genetics in clinical drug development: proceedings of a workshop. Washington, DC: The National Academies Press, 2017. https://www.ncbi.nlm.nih.gov/books/NBK441668/ (2017, accessed 19 December 2017).
